For the first time in over two decades, India’s pharma industry has barely had time to dust itself off from one crushing US FDA regulatory blow before another one was at hand. Almost all top 10-15 companies have had bans or third party audits slapped on their manufacturing plants. The collective impact has been devastating; to financials, the image of these companies and morale. The pharma index has slipped 18.3% since April last year, the first time in many years.
In the other emerging markets, which is the next big opportunity for Indian drug makers, countries like Russia and Venezuela have been battling economic crisis. Others, like Turkey, Brazil, and Mexico now insist on local manufacturing and technology transfer.
It’s that time of the year when the chickens are coming home to roost.
The quarterly result season is upon us. The post result analysis has been prescriptive for listed pharma companies, many of whom have had an awful run at the stock market so far. In a quiet disclosure to analysts last month, Lupin said it had added nearly a 1000 people to its field force, taking the total count to 5500. Another large pharma company is going to make a similar hiring announcement in the next quarter, say sources.
Did we not get to understand, just a few years ago, that most Indian pharma companies were cutting down medical representative hiring and “adopting technology to minimize the cost of marketing and promotion”? Whatever happened to that?
I guess desperate times call for desperate measures.
The spotlight is back on India. “Expect more Indian companies to invest in India because they are getting battered in the regulated market where price erosion is likely to reach low double digit from high single digit,” says an analyst with an international brokerage firm in Mumbai.
Too many cooks
Let’s back up a little.
In 2012, in the midst of a conversation at Cipla headquarters in Mumbai, Yusuf K Hamied, the affable chairman, blurted: “Most companies have already abandoned India…the government is pushing us out”. That year, Cipla’s revenue from exports was nearly 50%. By 2016, Hamied predicted it would go up to 75%.
Instead, exports only grew to 55% this year.
Cipla under Hamied was conservative in global expansion. But others were not.
Starting mid-1990s, in the first wave of entering regulated markets, Ranbaxy, Dr Reddy’s, Sun Pharma and Lupin entered the US generic market, which until then was dominated by companies like Teva, Mylan, Actavis and Sandoz.